Rationale for Targeting HER3 in NSCLC
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer

Released: December 26, 2023

Rebecca S. Heist
Rebecca S. Heist, MD, MPH
Helena Yu
Helena Yu, MD

Activity

Progress
1
Course Completed

This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs.